- Inspire Medical’s preliminary fourth-quarter 2024 revenue is projected to be between $239.5 million and $239.7 million, surpassing the estimate of $232.8 million.
- The company forecasts 2025 revenue to range from $940 million to $955 million, against an estimate of $950.7 million.
- Inspire Medical added 72 new medical centers in the U.S. during the fourth quarter of 2024, which brings the total to 1,435 centers offering Inspire therapy.
- In the fourth quarter of 2024, the company also established 12 new U.S. sales territories, increasing its total to 335 sales territories.
- The anticipated fourth-quarter revenue for 2024 represents approximately a 25% increase over the same quarter in 2023.
- The full-year 2025 revenue projection suggests a 17% to 19% increase over 2024.
- Investment analysts’ ratings include 14 buys, 5 holds, and no sells.
Inspire Medical Systems Inc on Smartkarma
Analyst coverage of Inspire Medical Systems Inc on Smartkarma indicates positive sentiment towards the company’s performance. Baptista Research published two reports on Inspire Medical Systems, highlighting key drivers of growth and success. In the report “Inspire Medical Systems: Is The New Inspire V System A Game Changer? – Major Drivers,” the company’s third-quarter revenue of $203.2 million, up 33% from the previous year, was attributed to increased adoption of Inspire therapy across new implanting centers and U.S. sales territories.
In another report titled “Inspire Medical Systems: Expanded Market Penetration Catalyzing Growth! – Major Drivers,” Inspire Medical Systems showcased significant growth and positive developments in the treatment of obstructive sleep apnea. With over 75,000 patients treated using Inspire therapy, the company has made notable strides in the medical solutions space. Baptista Research further aims to assess various factors influencing the company’s future stock price and conduct an independent valuation using a Discounted Cash Flow (DCF) methodology.
A look at Inspire Medical Systems Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 4 | |
| Resilience | 5 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
When looking at the long-term outlook for Inspire Medical Systems Inc using the Smartkarma Smart Scores, the company shows promise in several key areas. With a strong focus on growth and a resilient business model, Inspire Medical Systems Inc is positioned well for future expansion and sustainability. The company’s innovative approach to developing implantable neurostimulation systems for treating obstructive sleep apnea sets it apart in the medical technology sector.
Although there may be room for improvement in terms of value and dividend offerings, the high scores in growth and resilience indicate a positive trajectory for Inspire Medical Systems Inc. Additionally, the momentum score suggests that the company is gaining traction in the market. Overall, Inspire Medical Systems Inc‘s focus on technological advancements and healthcare solutions positions it as a key player in the industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars
